A network meta-analysis comparing CAPLYTA (lumateperone) with other FDA-approved atypical antipsychotics for adjunctive treatment of major depressive disorder (MDD) found CAPLYTA superior in efficacy across four key measures and showed no significant weight gain. Presented at the 2026 NEI Spring Congress, the analysis used data from 10 clinical trials and highlighted CAPLYTA's favorable safety profile, including lower risk of akathisia and weight gain compared to other treatments. These findings offer valuable indirect comparative insights to guide treatment decisions in the absence of direct head-to-head trials, supporting CAPLYTA as an effective adjunctive option for adults with MDD who do not respond adequately to antidepressants alone.
California retirees with dividend portfolios face significant state taxes that reduce their net income by about 23%, compared to states like Florida where the tax burden is much lower. Dividend yields vary by investment strategy: conservative portfol...
The Vanguard Dividend Appreciation Index Fund ETF (VIG) has posted a modest 5% gain year-to-date, underperforming the broader market due to rising long-term Treasury yields, which compete with dividend yields. While dividend growth continues, investo...
The FT Vest S&P 500 Dividend Aristocrats Target Income ETF (KNG) uses covered calls on Dividend Aristocrats stocks to deliver an 8.6% yield, appealing to retirees seeking income. However, this strategy caps upside gains, causing KNG to underperform t...
Johnson & Johnson and AbbVie both exceeded Q1 2026 revenue expectations, prompting them to raise their full-year guidance. JNJ's growth was driven by diversified pharma and MedTech segments, notably TREMFYA and cardiovascular products, while AbbVie r...
Vanguard Dividend Appreciation ETF (VIG) is often overlooked due to its low current yield of about 1.6%, but it focuses on companies with a strong history of dividend growth rather than high initial payouts. The fund tracks the S&P U.S. Dividend Grow...
